These are top 10 stocks traded on the Robinhood UK platform in July
On Thursday, Jefferies analysts downgraded Arvinas Inc. (NASDAQ:ARVN) stock from Buy to Hold and dramatically reduced their price target to $10.00 from the previous $52.00. This adjustment follows a decision by Arvinas and its partner, Pfizer (NYSE:PFE), to discontinue the development of their combination therapy for breast cancer, known as vepdeg, in both first-line and second-line or later treatments. The stock, currently trading at $7.23, has fallen over 70% in the past year, with analyst targets now ranging from $10 to $110. InvestingPro data shows the stock is currently trading below its Fair Value, with 13 additional real-time insights available to subscribers.
The change in rating and price target comes after consultations with health authorities and new data in the medical field indicated that estrogen receptor-targeted treatments might be limited to patients with ESR1 mutations in second-line or later breast cancer therapies. The analysts noted that while vepdeg monotherapy could still represent a significant opportunity in the second-line or later treatment of ESR1 mutant ER+/HER2- breast cancer, they had anticipated the combination therapy to be the more substantial prospect. Despite recent challenges, InvestingPro data reveals the company maintains a strong financial position with a current ratio of 4.64 and more cash than debt on its balance sheet.
Jefferies had previously modeled a peak sales estimate of approximately $400 million for vepdeg monotherapy in this specific patient population. However, due to the discontinuation of the combination therapy and the fact that other pipeline assets are considered too early-stage to assign value, the firm has opted to downgrade the stock.
The announcement has led to a reassessment of Arvinas’ potential revenue and growth prospects, prompting Jefferies to issue a new price target. The firm’s decision reflects the reduced expectations for the company’s development pipeline following the latest update on its breast cancer treatment strategy.
In other recent news, Arvinas Inc. reported impressive financial results for Q1 2025, with revenues reaching $188.8 million, significantly exceeding the forecast of $42.16 million. The company also reported earnings per share of $1.14, highlighting its strong financial performance. Despite these positive results, Arvinas announced a strategic shift by halting Phase 3 trials in collaboration with Pfizer for ER+ breast cancer treatments, focusing instead on cost reduction and early-stage drug development. Goldman Sachs responded to these developments by lowering its price target for Arvinas to $8, maintaining a Neutral rating. The decision to discontinue the trials was influenced by the strategic realignment to focus on the company’s early-stage pipeline and extend its financial runway into the second half of 2028. Arvinas also announced a restructuring plan, including workforce reductions and portfolio reprioritization, aiming to save approximately $80 million annually. These recent developments reflect Arvinas’s efforts to navigate challenges while capitalizing on its strong financial position and promising drug pipeline.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.